HGF and pancreatic neoplasm: Thus, we submit that a therapeutic strategy involving HGF/c-MET inhibition with or without chemotherapy, is eminently ready to be taken to clinical trials for pancreatic cancer in both neoadjuvant and adjuvant scenarios.